🔴 Insmed is trading 4.6% down with no clear company-specific catalyst identified

Insmed is trading 4.6% down at $108.89, with no clear company-specific announcement explaining the October 1 decline.

• The latest identified company-specific news was Barclays lowering its price target while maintaining its rating on September 30.
• The decline coincides with a sharp rise in Treasury yields. Reuters reported the 10-year yield reached 5.306%, its highest since mid-June 2007, amid persistent inflation concerns.
• Higher yields may weigh on growth-sensitive biotech shares, but available reporting does not directly link them to Insmed’s decline.